R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Landscape of genetic alterations in patients with metastatic uveal melanoma.
Sophie Piperno-Neumann,Ellen Kapiteijn,James Larkin,Richard D. Carvajal,Jason J. Luke,Heike Seifert,Inge Roozen,Mustapha Zoubir,Thiruvamoor Ramkumar,Caroline Emery,Adnan Derti,Padmaja Yerramilli-Rao,F. Stephen Hodi,Gary K. Schwartz +13 more
TL;DR: In this article, Uveal melanoma (UM) is a rare type of cancer with a mutational profile distinct from skin melanoma and poor prognosis in a metastatic setting.
Journal ArticleDOI
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
Firas S. Ahmed,Laurent Dercle,Gregory V. Goldmacher,Hao Yang,Dana E. Connors,Ying Tang,Sanja Karovic,Binsheng Zhao,Richard D. Carvajal,Caroline Robert,Michael L. Maitland,Geoffrey R. Oxnard,Lawrence H. Schwartz +12 more
TL;DR: Effectiveness of immunotherapy in clinical trials depends on the criterion used to assess tumor response (RECIST 1.1 vs iRECist) with iRECIST being more appropriate to detect pseudoprogression and potentially prevent premature termination of effective therapy.
Journal ArticleDOI
Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.
Alexander N. Shoushtari,Sandra P. D'Angelo,Mary Louise Keohan,Mark A. Dickson,Mrinal M. Gounder,Abdul Karim Abdullah,Joseph P. Erinjeri,Mark J. Bluth,Yelena Ustoyev,Mercedes M. Condy,Howard Streicher,Naoko Takebe,Ronald P. DeMatteo,Gary K. Schwartz,William D. Tap,Richard D. Carvajal +15 more
TL;DR: A murine GIST model showed that the efficacy of KIT inhibition is immune-mediated via decreases in indoleamine 2,3-dioxygenase (IDO), with improved anti-tumor effects using combined KIT and CTLA-4 blockade.
Journal ArticleDOI
Melanoma driver mutations and immune therapy
Douglas B. Johnson,Christine M. Lovly,Ryan J. Sullivan,Richard D. Carvajal,Jeffrey A. Sosman +4 more
TL;DR: Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear, and it is found that clinical outcomes were largely superior in those with NRAS mutations.
Journal ArticleDOI
DQueST: dynamic questionnaire for search of clinical trials.
TL;DR: DQueST contributes a novel framework for transforming free-text eligibility criteria to questions and filtering out clinical trials based on user answers to questions dynamically, which promises to augment keyword-based methods to improve clinical trial search.